ATE516348T1 - Glykoprotein vi und dessen anwendungen - Google Patents

Glykoprotein vi und dessen anwendungen

Info

Publication number
ATE516348T1
ATE516348T1 AT00946953T AT00946953T ATE516348T1 AT E516348 T1 ATE516348 T1 AT E516348T1 AT 00946953 T AT00946953 T AT 00946953T AT 00946953 T AT00946953 T AT 00946953T AT E516348 T1 ATE516348 T1 AT E516348T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid molecules
glycoprotein
expression vectors
provides isolated
Prior art date
Application number
AT00946953T
Other languages
English (en)
Inventor
Samantha Busfield
Jean-Luc Villelal
Martine Jandrot-Perrus
William Vainchencker
Davinder Gill
Ming Qian
Gillian Kingsbury
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27407686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE516348(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/345,468 external-priority patent/US6245527B1/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE516348T1 publication Critical patent/ATE516348T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00946953T 1999-06-30 2000-06-30 Glykoprotein vi und dessen anwendungen ATE516348T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/345,468 US6245527B1 (en) 1999-06-30 1999-06-30 Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US45482499A 1999-12-06 1999-12-06
US09/503,387 US7291714B1 (en) 1999-06-30 2000-02-14 Glycoprotein VI and uses thereof
PCT/US2000/018152 WO2001000810A1 (en) 1999-06-30 2000-06-30 Glycoprotein vi and uses thereof

Publications (1)

Publication Number Publication Date
ATE516348T1 true ATE516348T1 (de) 2011-07-15

Family

ID=27407686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00946953T ATE516348T1 (de) 1999-06-30 2000-06-30 Glykoprotein vi und dessen anwendungen

Country Status (5)

Country Link
US (5) US7291714B1 (de)
EP (3) EP1190043B1 (de)
AT (1) ATE516348T1 (de)
AU (1) AU6063500A (de)
WO (1) WO2001000810A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2341141T3 (en) * 1999-05-07 2015-04-20 Sanofi Aventis Deutschland Antibodies to recombinant platelet kollagenreceptorglycoprotein VI
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20090311267A1 (en) * 1999-08-10 2009-12-17 University Of Wurzburg Inhibition of VWF - GPIb/V/IX interaction and platelet-collagen interaction for prevention and treatment of cerebral attacks
AU7097400A (en) 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (de) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
CA2451680C (en) * 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
EP1406929A2 (de) * 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusionproteine
GB0130543D0 (en) * 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1369128A1 (de) 2002-06-07 2003-12-10 Procorde GmbH Glycoprotein VI Inhibitoren und deren therapeutische Verwendung
EP1538165A1 (de) * 2003-12-03 2005-06-08 Procorde GmbH Glycoprotein VI Inhibitoren auf der Basis des monoklonalen Antikörpers hgp 5c4
GB0511590D0 (en) * 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
US7645592B2 (en) * 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
ES2389047T3 (es) * 2004-04-29 2012-10-22 Otsuka Pharmaceutical Co., Ltd. Anticuerpos específicos contra la glicoproteína VI y procedimientos de producción de estos anticuerpos
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
EP1937815B1 (de) 2005-09-13 2015-05-13 National Research Council of Canada Verfahren und zusammensetzungen zur modulation der tumorzellaktivität
EP1916259A1 (de) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-Glycoprotein VI SCFV Fragment zur Thrombosebehandlung
US8278271B2 (en) * 2006-12-13 2012-10-02 University Of Massachusetts Inhibiting collagen-induced platelet aggregation and activation with peptide variants
US9410744B2 (en) 2010-05-12 2016-08-09 Molten Metal Equipment Innovations, Llc Vessel transfer insert and system
CA2722018A1 (en) * 2008-04-22 2009-10-29 Csl Behring Gmbh Method for the prevention and treatment of cancer by inhibition of gpvi
WO2010111240A2 (en) * 2009-03-23 2010-09-30 The Brigham And Women's Hospital, Inc. Methods for treating inflammatory arthritis
US8889645B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US8889646B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US8318923B2 (en) * 2009-06-03 2012-11-27 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US9108244B2 (en) 2009-09-09 2015-08-18 Paul V. Cooper Immersion heater for molten metal
PT2504363T (pt) 2009-11-24 2019-08-02 Nat Res Council Canada Anticorpos anticlusterina e fragmentos de ligação ao antigénio e a sua utilização para reduzir o volume de um tumor
EP2336188A1 (de) * 2009-12-18 2011-06-22 Sanofi-Aventis Neuartige Antagonistenantikörper und ihre FAB-Fragmente gegen GPVI und Verwendungen davon
EP2397495A1 (de) * 2010-06-21 2011-12-21 Sanofi Neuartige Antagonistenantikörper und ihre FAB-Fragmente gegen GPVI und Verwendungen davon
MX347613B (es) 2009-12-18 2017-05-04 Sanofi Sa Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos.
EP2402371A1 (de) * 2010-07-01 2012-01-04 Sanofi Neuartige Antagonistenantikörper und ihre FAB-Fragmente gegen GPVI und Verwendungen davon
US20130217050A1 (en) 2010-09-07 2013-08-22 Mochida Pharmaceutical Co., Ltd. Method for diagnosing alzheimer's disease using-soluble gpvi
EP2646827A1 (de) 2010-12-01 2013-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und kits zur bestimmung der plättchenempfindlichkeit zur aktivierung in einem patienten
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
JP7076082B2 (ja) 2015-08-05 2022-05-27 アクティコー バイオテック 新規な抗ヒトｇｐｖｉ抗体およびその使用
CN110494447B (zh) 2017-02-03 2024-06-04 艾科迪科尔生物技术公司 使用抗人gpv1抗体抑制血小板聚集
US11542329B2 (en) 2018-05-16 2023-01-03 Morphosys Ag Antibodies targeting Glycoprotein VI
WO2022212470A2 (en) * 2021-03-31 2022-10-06 Janssen Biotech, Inc. Materials and methods for immune effector cells redirection

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474893A (en) * 1892-05-17 Peanut-cleaner
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1541682A3 (de) 1988-09-02 2005-07-06 Dyax Corp. Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
EP0950707B1 (de) 1989-07-25 2009-02-18 Cell Genesys, Inc. Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
AU635844B2 (en) 1989-11-06 1993-04-01 Cell Genesys, Inc. Production of proteins using homologous recombination
US5874289A (en) * 1989-11-17 1999-02-23 Abbott Laboratories Bacillus thuringiensis mutants which produce high yields of crystal delta-endotoxin
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5198342A (en) * 1990-07-05 1993-03-30 Immunex Corporation DNA encoding IgA Fc receptors
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
IL98764A0 (en) 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69130709T3 (de) 1990-10-05 2005-12-22 Celldex Therapeutics, Inc. Gezielte immunostimulierung mit bispezifischen stoffen
EP0557300B1 (de) 1990-10-29 1997-11-19 Chiron Corporation Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69214709T2 (de) 1991-04-26 1997-02-20 Surface Active Ltd Neue Antikörper und Verfahren zu ihrer Verwendung
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0627940B1 (de) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69333969T2 (de) 1992-10-30 2006-09-14 The General Hospital Corp., Boston Wechselwirkendes Fallensystem zur Isolierung von Proteinen
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
JP3720049B2 (ja) 1993-10-22 2005-11-24 トライジェン・リミテッド 血小板由来増殖因子アナログ
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5763199A (en) 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU5927398A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Fc receptors and polypeptides
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6448035B1 (en) * 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
AU9222698A (en) 1997-09-05 1999-03-22 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof
US6194151B1 (en) 1997-09-26 2001-02-27 Millenium Pharmaceuticals, Inc. Molecules of the TNF receptor superfamily and uses therefor
DK2341141T3 (en) 1999-05-07 2015-04-20 Sanofi Aventis Deutschland Antibodies to recombinant platelet kollagenreceptorglycoprotein VI
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
ES2389047T3 (es) 2004-04-29 2012-10-22 Otsuka Pharmaceutical Co., Ltd. Anticuerpos específicos contra la glicoproteína VI y procedimientos de producción de estos anticuerpos

Also Published As

Publication number Publication date
EP1190043A1 (de) 2002-03-27
EP2902414A1 (de) 2015-08-05
AU6063500A (en) 2001-01-31
EP1190043A4 (de) 2004-12-29
US7597888B2 (en) 2009-10-06
EP2322558A1 (de) 2011-05-18
US20100261200A1 (en) 2010-10-14
WO2001000810A1 (en) 2001-01-04
US6989144B1 (en) 2006-01-24
EP1190043B1 (de) 2011-07-13
US8137923B2 (en) 2012-03-20
EP2322558B1 (de) 2015-01-07
US7291714B1 (en) 2007-11-06
US20080050380A1 (en) 2008-02-28
US20060216291A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
ATE516348T1 (de) Glykoprotein vi und dessen anwendungen
DE60033293D1 (de) Neue b7-4 moleküle und deren verwendungen
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
DE69837104D1 (de) An g-protein gekoppelte rezeptoren und deren verwendungen
DE69837268D1 (de) Neue moleküle aus der familie der tango-77-ähnlichen proteine und ihre verewendungen.
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
WO2002044354A3 (en) Molecules of the card-related protein family and uses thereof
DE60031418D1 (de) 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
EP1710299A3 (de) Sekretierte Proteine und dafür kodierende Polynukleotide
WO2000039149A3 (en) Secreted proteins and uses thereof
WO2001061005A3 (en) Molecules of the pyrin domain protein family and uses thereof
WO2002103015A3 (en) Abca10 transporter
DE60237613D1 (de) Neue pgc-1-isoformen und deren verwendungen
WO2001000673A8 (en) Membrane-associated and secreted proteins and uses thereof
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
DE60138952D1 (de) 16836, ein mitglied der humanen phospholipase c familie und seine verwendungen
WO2000050442A3 (en) Secreted proteins and uses thereof
ATE349515T1 (de) 13245, eine neue, humane protein kinase vom typ myotonische dystrophie protein kinase und anwendungen davon
DE60136832D1 (de) Atcr-1, eine humane acyltransferase und verwendungen davon
WO2000039150A3 (en) Secreted proteins and uses thereof
ATE476194T1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür
ATE445714T1 (de) 15603, ein mitglied der humanen ionenkanal- familie
ATE331033T1 (de) Proteinkinase-molekül 14911 und dessen anwendungen
WO2001074854A3 (en) 32449, a putative human transporter and uses thereof
DE60139153D1 (de) 14189, eine humane kinase und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties